Latest International Sales News

Page 1 of 9
TJX delivered a stronger-than-planned third quarter, with comparable sales up 4% and diluted earnings per share rising 9% to US$1.39. The result included a US$77 million pretax benefit from tariff refunds, but adjusted earnings and margins also exceeded the company’s plan.
Logan Eniac
Logan Eniac
19 Nov 2026
Biome Australia has secured an exclusive mainland China cross-border e-commerce agreement with H&S Global, targeting A$2.0 million in Year 1 purchases from an early 2027 launch. The target is larger than Biome’s entire FY26 international sales, but the company will fund 25% of Year 1 invoiced value in marketing and operational support.
Ada Torres
Ada Torres
9 Nov 2026
Mayne Pharma will sell its international operations, including the Salisbury manufacturing site, to Evaris Pharma for $55.5 million in cash. The deal leaves the company focused entirely on its US Women’s Health, Dermatology and DistributeRx businesses, subject to ACCC approval.
Victor Sage
Victor Sage
6 Nov 2026
Monster Beverage delivered a strong third quarter, with sales rising 16.7% to US$2.56 billion and international revenue climbing 28.1%. The trade-off was narrower margins as aluminium, freight, fuel, marketing and transformation costs increased.
Victor Sage
Victor Sage
6 Nov 2026
Insulet delivered a stronger-than-expected third quarter, with revenue up 19.2% and adjusted earnings per share rising nearly 60%. The diabetes-device maker also raised its operating-margin outlook and authorised a US$1 billion share repurchase programme.
Ada Torres
Ada Torres
4 Nov 2026
Keurig Dr Pepper delivered a sharp third-quarter sales and adjusted earnings lift, helped by the newly acquired JDE Peet’s coffee business and a US$99 million tariff refund. The company reaffirmed its 2026 targets while carrying substantial acquisition-related debt and integration work.
Victor Sage
Victor Sage
4 Nov 2026
Sigma Healthcare has entered FY27 with double-digit Chemist Warehouse sales growth, stronger earnings and a merger integration program targeting $100 million in annual synergies by FY29. The next test is whether store expansion and technology consolidation can convert momentum into durable cash returns.
Ada Torres
Ada Torres
21 Oct 2026
XRF Scientific has delivered its strongest September quarter in years, with revenue rising 38% to $21.1 million and profit before tax climbing 30% to $4.4 million. Orbis growth, resilient consumables demand and the developing CGA business are giving the company several avenues for further expansion, although precious metals revenue included a low-margin one-off sale.
Victor Sage
Victor Sage
13 Oct 2026
Memphasys will receive an A$3.5 million advance from major shareholder Peters Investments to expand Felix production, inventory and sales capacity as repeat orders emerge across international markets. The funding carries a 12.5% interest rate, potential equity dilution and requires shareholder and ASX approvals before the convertible notes can be issued.
Ada Torres
Ada Torres
29 Sept 2026
Rua Bioscience delivered a sharp rise in customer revenue and secured a UK agreement expected to generate NZ$10 million over two years. But PwC disclaimed an audit opinion, warning the company may not have enough cash without another capital raise.
Ada Torres
Ada Torres
22 Sept 2026
Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.
Ada Torres
Ada Torres
31 Aug 2026
SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.
Ada Torres
Ada Torres
28 Aug 2026

Browse the archive

Full archive